Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Current standard-of-care therapies provide median survival of only 14-15 months, highlighting the urgent need for novel therapeutic approaches
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
A great effort has been paid to find drugs and treatments for hospitalized, severely ill patients
L- , , ,
According to the release from Johnson & Johnson , for the treatment of UC, guselkumab is administered as a 200 mg induction dose intravenously at weeks zero, 4, and 8 by a healthcare professional
Long-term Use : Prolonged use beyond a few months should be approached with caution
/product/41/5015682/1.jpg?5024)
